Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Joincare Pharmaceutical Group Industry Co., Ltd. has obtained the drug registration certificate for its inhaled powder and mist of salmeterol and fluticasone.

Time Posted:2024-06-14 11:20

On June 12, 2024, Joincare Pharmaceutical Group Industry Co., Ltd. announced that it had received the Drug Registration Certificate issued by the National Medical Products Administration, marking the official approval of the marketing of its inhaled powder and mist formulation of salmeterol and fluticasone (hereinafter referred to as "the product"). This news not only brings huge market opportunities for Health and Wellness, but also provides new treatment options for relevant patients.

Jiankangyuan Pharmaceutical Group's two major products achieve key progress, high-quality foundation builds professional R&D achievements

Time Posted:2024-06-14 11:18

Jiankangyuan recently received good news in the high-end segment of pharmaceutical R&D. Two of its key products have made key progress, demonstrating the company's strong capabilities in drug R&D and bringing new treatment options for patients.

Lizhu Pharmaceutical has reached an exclusive development and commercialization licensing agreement with Xuanzhu Bio for its product, Fudanafi (XZP-5849).

Time Posted:2024-06-13 21:15

Recently, Lizhu Pharmaceutical Group Co., Ltd.'s wholly-owned subsidiary, Lizhu Pharmaceutical Factory (hereinafter referred to as "Lizhu Pharmaceutical"), and Xuanzhu Biotechnology Co., Ltd. (hereinafter referred to as "Xuanzhu Biotechnology"), a non-wholly-owned subsidiary of Four Rings Pharmaceutical Holdings Group Co., Ltd., jointly announced that the two parties have reached an exclusive licensing cooperation agreement on Xuanzhu Biotechnology's independently developed highly selective PDE-5 inhibitor, Vardenafil (product code: XZP-5849).

Healthy Yuan Holdings subsidiary, Lizhu Pharmaceutical: Setting sail on a new antifungal track

Time Posted:2024-06-04 19:12

Recently, Joincare Pharmaceutical Group Industry Co., Ltd.'s holding subsidiary, Lizhu Pharmaceutical Group Co., Ltd., and its wholly-owned subsidiary, Lizhu Pharmaceutical Factory (hereinafter referred to as "Lizhu Pharmaceutical"), jointly announced with Shenzhen Xianggen Bio-Technology Co., Ltd. (hereinafter referred to as "Xianggen Bio"), a company focusing on innovative drugs for antifungal infections and oral cyclic peptide innovative drug platforms, that the two parties have reached a strategic cooperation and signed a Greater China rights transaction agreement for SG1001.

Lizhu Pharmaceutical: Setting Sail on a New Antifungal Track

Time Posted:2024-06-04 16:10

Recently, Lizhu Pharmaceutical Group Co., Ltd.'s wholly-owned subsidiary, Lizhu Pharmaceutical Factory (hereinafter referred to as "Lizhu Pharmaceutical"), and Shenzhen Xianggen Bio-Technology Co., Ltd. (hereinafter referred to as "Xianggen Bio"), which focuses on innovative drugs for antifungal infections and oral cyclic peptide innovative drug platforms, jointly announced that the two parties have reached a strategic cooperation on SG1001 and signed a Greater China rights transaction agreement.

Medical consultation, medicine delivery, and health delivery: Healthy Yuan & Lizhu Pharmaceutical chronic disease public welfare program builds dreams in the 28th town's rural revitalization

Time Posted:2024-05-22 19:22

To improve the understanding and prevention and control capabilities of chronic diseases among the grassroots population and help solve the difficulties faced by ordinary people in accessing medical care and medication, a "Healthy Yuan, Lizhu Pharmaceutical Chronic Disease Public Welfare Support for Rural Revitalization" and Jiangshan City Chronic Disease Free Clinic and Drug Delivery event was held in the Xunli Village hall in the 28th Du Town of Jiangshan City on the morning of May 22. Zhou Junwang, president of the Jiangshan City Charity Federation, Zhou Shunfu, director of the Municipal Health and Health Bureau, and other relevant leaders, as well as volunteers from the Taohuayuan Foundation, Healthy Yuan, and Lizhu Pharmaceutical attended the event. At the launch ceremony, Healthy Yuan and Lizhu Pharmaceutical donated cardiovascular, hypertension, hyperlipidemia, and gastric disease medications worth 1 million yuan to the Jiangshan City area, planning to fully launch the "2024 Healthy Yuan, Lizhu Pharmaceutical Chronic Disease Public Welfare Support for Rural Revitalization" campaign in urban and rural areas of the city. In addition, a free clinic was also held on-site, attracting local chronic disease patients and village representatives. It is understood that the donated chronic disease medications will be distributed in batches according to local conditions to help chronic disease patients in difficult families and reduce their medical burden. The first batch of medications was distributed at this event.

Chronic disease public welfare benefits extended to Tuoketuo County, Inner Mongolia. Health Yuan & Lizhu Pharmaceutical support the construction of healthy rural areas with medicine.

Time Posted:2024-05-22 19:00

On May 22, the "Chronic Disease Public Welfare Project to Support Rural Revitalization," jointly promoted by Health Yuan and Lizhu Group, arrived in Toktok County, Inner Mongolia Autonomous Region, where a donation ceremony was held at the County Party and Government Conference Center. Zhang Xiaodong, member of the Standing Committee of the County Committee and Deputy County Head; Nasen Ulitu, Deputy Director of the Government Office; leaders from the County Health and Health Commission and the County Red Cross Society; and volunteers from Health Yuan and Lizhu Group attended the event. Toktok County is located in the central part of Inner Mongolia Autonomous Region, on the Tumot Plain at the northern bank of the boundary between the upper and middle reaches of the Yellow River and the southern foot of Daqing Mountain. In recent years, the county has vigorously implemented the "Rural Talents Supporting Rural Revitalization" action, calling on rural talents in the medical field to take root at the grassroots level, popularize health knowledge, and effectively solve problems in disease prevention, diagnosis, treatment, and post-illness difficulties. 2024 is a year for deepening the effective connection between consolidating the achievements of poverty alleviation and rural revitalization. The economic burden caused by disease is one of the most prominent factors and a key area needing improvement in supporting rural revitalization. Establishing a long-term chronic disease prevention and control system is an important part of rural revitalization work. With the development of the economy and society, especially the aging population and changes in residents' production and lifestyles, the incidence of chronic diseases in China has generally shown an upward trend and is becoming younger. Data from the seventh national census in China shows that in 2023, there were approximately 180 million chronic disease patients in China. Among them, low-income patients in remote areas face significant challenges in medical security, including the accessibility and affordability of medicines. Chronic disease prevention and control work in Toktok County is one of the important directions for the county's health undertakings and rural revitalization work. The 1 million yuan worth of chronic disease treatment drugs donated by Health Yuan and Lizhu Group will effectively support the county's comprehensive chronic disease prevention and control construction, reduce the economic burden on local patients, and prevent low-income families from falling into or returning to poverty due to illness. This year marks the seventh year of the Health Yuan and Lizhu Group chronic disease public welfare project. Since the end of 2018, Health Yuan, relying on its pharmaceutical company advantages, has donated chronic disease medicines to remote areas across the country many times, effectively helping to improve the level of basic medical services.

March 2024

Time Posted:2024-05-20 16:53

Through collaboration with Bayer, we have obtained the exclusive license for the domestic development, commercialization, and production of an oral drug for COPD. This drug works by inhibiting prolyl endopeptidase (PREP) activity, preventing the production of COPD inflammatory mediators, and is expected to bring new treatment strategies for COPD patients.

< 1...91011...55 >